Merck Publishes 2010 Global Corporate Responsibility Report

MerckMerck (NYSE: MRK), known as MSD outside the United States and Canada, launched its 2010 global corporate responsibility report, which emphasizes the importance of discovering better ways of doing business to benefit both society and its business.

"Our world is changing rapidly. We recognize that expectations for companies like Merck are now higher than ever before," said Kenneth C. Frazier, president and CEO, Merck. "We, of course, need to continue to be both innovative and profitable, but need to do so in a way that protects the environment, supports communities, respects employees, and demonstrates ethical behavior."

The report covers Merck's corporate responsibility activities, progress, goals and performance during 2010 in four focus areas that the company identified as critical to our business: Access to Health, Environmental Sustainability, Employees, and Ethics and Transparency. It includes metrics related to each area of focus and announces a new set of key performance indicators (KPIs) that will be used in the coming years to measure progress in each area of focus.

Merck continues to use several external reporting guidelines including the Global Reporting Initiative (GRI 3.1) Guidelines, The Millennium Development Goals, the Access to Medicines Index, and the United Nations Global Compact Communication on Progress.

Discovering innovative solutions to some of the world's greatest health challenges
This year's report is themed "Discovering," highlighting Merck's commitment to discovering innovative solutions to some of the world's greatest health challenges.

  • Access to Health: The report highlights Merck's efforts and performance in facilitating greater access to healthcare, particularly for underserved populations. In early 2011, Merck introduced a Statement of Guiding Principles to guide its worldwide approach to access to health; the principles outline specific goals to assure progress across Merck's business, from R&D and the supply chain, to commercialization and investment in local infrastructure.
  • Environmental Sustainability: The report highlights the company's respect for the earth's resources with a commitment to discover environmentally sustainable ways to meet the world's health needs. It includes Merck's recently established environmental goals and a road map that will guide the company's progress, from reducing its environmental footprint in the short term, to transforming its entire value chain over the longer term.
  • Employees: The report highlights the company's efforts to create a work environment that allows both its employees and its business to thrive. Merck is committed to supporting its employees by developing resources and opportunities that help employees grow professionally, helping to improve the health of its employees and their families, and encouraging them to get involved in their communities in ways that are meaningful.
  • Ethics and Transparency: The report also reviews Merck's commitment to ethical behavior and transparent communications across its global business and how it is working to earn the trust of customers, patients and stakeholders critical to its business.

In addition to the comprehensive report at www.merckresponsibility.com, Merck has published an overview of its corporate responsibility approach and activities that, through profiles of employees and patients, brings to life its areas of focus and highlights various programs and partnerships that exemplify Merck's corporate responsibility commitments. The overview is available on Merck's corporate responsibility Web site; hard copies can be requested online.

About Merck
Today's Merck is a global healthcare leader working to help the world be well. Merck is known as MSD outside the United States and Canada. Through our prescription medicines, vaccines, biologic therapies, and consumer care and animal health products, we work with customers and operate in more than 140 countries to deliver innovative health solutions. We also demonstrate our commitment to increasing access to healthcare through far-reaching policies, programs and partnerships.

Most Popular Now

AstraZeneca amends collaboration with Ironwood for…

AstraZeneca has amended its collaboration agreement with Ironwood Pharmaceuticals, Inc. (Ironwood) in China mainland, China Hong Kong and China Macau for Linzess (linaclo...

Cause of antibiotic resistance identified

Scientists have confirmed for the first time that bacteria can change form to avoid being detected by antibiotics in the human body. Studying samples from elderly patient...

Bayer, Brigham and Women’s Hospital, and Massachus…

Bayer and Partners HealthCare's founding members Brigham and Women's Hospital (BWH) and Massachusetts General Hospital (MGH) today announced the launch of a joint lab to ...

FDA grants Fast Track designation for Farxiga in h…

AstraZeneca announced that the US Food and Drug Administration (FDA) has granted Fast Track designation for the development of Farxiga (dapagliflozin) to reduce the risk ...

Amgen announces positive results from two Phase 3 …

Amgen (NASDAQ:AMGN) today announced that the results of a prespecified interim analysis of an open-label, randomized, controlled global multicenter Phase 3 trial (2012021...

Brilinta monotherapy in high-bleeding risk patient…

New data from TWILIGHT, a Phase IV independent trial (funded by AstraZeneca), showed that in patients at high-bleeding risk who underwent PCI and completed 3 months of du...

Gene-targeted cancer drugs, slow release overcome …

Biomedical engineers at Duke University have developed a method to address failures in a promising anti-cancer drug, bringing together tools from genome engineering, prot...

Educational campaign helps teens and their caregiv…

Teenagers face many challenges, and growing up with a chronic skin disease called atopic dermatitis (AD) can impact the ups and downs and transitions to young adulthood. ...

Study points to new drug target in fight against c…

Researchers have identified a potential new drug target in the fight against cancer. In a study this week in the Proceedings of the National Academy of Sciences, an inter...

AstraZeneca divests rights for Losec to Cheplaphar…

AstraZeneca has agreed to sell the global commercial rights, excluding China, Japan, the US and Mexico, for Losec (omeprazole) and associated brands to Cheplapharm Arznei...

Cheaper drug just as effective protecting heart in…

A new clinical trial conducted at The Ohio State University Wexner Medical Center found a cost-effective generic medication works just as well as a more expensive drug in...

Dengue virus becoming resistant to vaccines and th…

Researchers from Duke-NUS Medical School (DukeNUS), in collaboration with the Agency for Science, Technology and Research (A*STAR)'s Bioinformatics Institute (BII), and t...